Selective Androgen Receptor Modulators Activate the Canonical Prostate Cancer Androgen Receptor Program and Repress Cancer Growth

The authors investigated the antitumor effects of selective androgen receptor (AR) modulators (SARMs), which are small-molecule nonsteroidal AR agonists developed to treat muscle wasting and cachexia. Several orally administered SARMs activated the AR program in prostate cancer models